Related Experiment Video
Updated: Jun 19, 2026
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Taxomyces andreanae: a presumed paclitaxel producer demystified?
Agata Staniek1, Herman J Woerdenbag, Oliver Kayser
1Pharmaceutical Biology Department, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
Abstract:
The 1990s brought an abundance of reports on paclitaxel-producing endophytes, initially heralded as a discovery having tremendous implications for cancer therapy. As the vision of large-scale fermentation tanks producing vast quantities of relatively inexpensive paclitaxel and novel taxanes has faded and has been replaced by controversial silence, we carried out an in-depth investigation of Taxomyces andreanae - the very first presumed endophytic synthesizer of the diterpenoid. On one hand, metabolic profiling by means of chromatographic, spectroscopic and immunoenzymatic techniques predominant in literature was taken up. On the other, the experimental procedure was brought to an alternative, previously unattempted level aiming at revealing the genetic background of paclitaxel biosynthesis in the endophyte. The profound PCR-based screening for taxadiene synthase (TXS) - a gene unique to the formation of the primary taxane-skeleton, as well as phenylpropanoyl transferase (BAPT) encoding for the catalyst of the final acylation of the core structure rendering the ultimate efficacy of the drug, confirmed the molecular blueprint for paclitaxel biosynthesis to be an inherent genetic trait of the endophyte. However, as the thorough metabolic analysis of Taxomyces andreanae commercial isolate brought no confirmation of endophytic paclitaxel production even after considerable up-scaling endeavors, we postulate that proclaiming the strain "a fungus factory for Taxol" might have been premature.
Insights
Paclitaxel (Taxol) production by the endophyte Taxomyces andreanae was investigated. While the fungus possesses the genes for paclitaxel biosynthesis, metabolic analysis did not confirm actual production, suggesting claims of it being a "fungus factory" may be premature.
Area of Science:
- Microbial biotechnology
- Natural product chemistry
- Cancer therapeutics
Background:
- Paclitaxel (Taxol) is a crucial chemotherapy agent derived from natural sources.
- Endophytes, particularly Taxomyces andreanae, were initially identified as potential sources for paclitaxel production.
- The early promise of large-scale endophytic paclitaxel synthesis has been met with limited success and controversy.
Purpose of the Study:
- To investigate the endophytic paclitaxel production capabilities of Taxomyces andreanae.
- To confirm the genetic basis for paclitaxel biosynthesis within the endophyte.
- To reconcile the genetic potential with actual metabolic output.
Main Methods:
- Metabolic profiling using chromatographic, spectroscopic, and immunoenzymatic techniques.
- Polymerase Chain Reaction (PCR)-based screening for key paclitaxel biosynthesis genes (TXS and BAPT).
- Cultivation and metabolic analysis of Taxomyces andreanae under scaled-up conditions.
Main Results:
- The genetic blueprint for paclitaxel biosynthesis, including taxadiene synthase (TXS) and phenylpropanoyl transferase (BAPT) genes, was confirmed as an inherent trait of Taxomyces andreanae.
- Despite possessing the necessary genes and up-scaling efforts, metabolic analysis failed to detect paclitaxel production in the commercial isolate.
- The study found no evidence of paclitaxel synthesis by the investigated endophytic strain.
Conclusions:
- Taxomyces andreanae harbors the genetic machinery for paclitaxel biosynthesis.
- The absence of detectable paclitaxel production challenges the notion of this endophyte as a viable "fungus factory" for Taxol.
- Further research is needed to understand the regulation and limitations of paclitaxel biosynthesis in endophytic fungi.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:31Taxonomy